Contineum Therapeutics, Inc. · NASDAQ:CTNM
Lorrain Daniel S. sold 37,179 Contineum Therapeutics, Inc. shares (Form 4)
Traded Jun 30 to Jul 1, 2026 · Filed Jul 2, 2026
From Jun 30 to Jul 1, 2026, Lorrain Daniel S. (Chief Scientific Officer) sold 37,179 Contineum Therapeutics, Inc. shares at an average US$16.00 for US$595K under a trading plan, leaving 135,202 shares. Filed Jul 2, 2026 (Form 4).
- Sold
- 37,179 shares
- Price
- US$16.00 average (US$15.67 to US$16.24)
- Value
- US$595K
- Holding after
- 135,202 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Scientific Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Class A Common Stock | Option exercise | 28,826 | US$1.01 | 168,198 | Direct |
| Jun 30, 2026 | Class A Common Stock | Sale | 28,826 | US$16.04 | 139,372 | Direct |
| Jul 1, 2026 | Class A Common Stock | Option exercise | 4,183 | US$1.01 | 143,555 | Direct |
| Jul 1, 2026 | Class A Common Stock | Sale | 5,852 | US$15.67 | 137,703 | Direct |
| Jul 1, 2026 | Class A Common Stock | Sale | 2,501 | US$16.24 | 135,202 | Direct |
Source
Related
- Contineum Therapeutics, Inc.
- Lorrain Daniel S.
- Contineum Therapeutics, Inc. shareholders
- Form 4 · Lorrain Daniel S. · Jul 10, 2026
- Form 4 · Lorrain Daniel S. · Jun 1, 2026
- Form 4 · Lorrain Daniel S. · May 1, 2026
- Form 4 · Lorrain Daniel S. · Apr 6, 2026
- Form 4 · Stengone Carmine N. · Sep 8, 2026
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Form 4 · Stengone Carmine N. · Aug 3, 2026
- Schedule 13G · BlackRock, Inc. · Jul 27, 2026
- Schedule 13G/A · Millennium Management LLC · Jul 17, 2026